ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Other Working Capital
Cash effect of changes in other operating assets and liabilities.
Other Working Capital history
Currency unavailable · from the cash flow
No Other Working Capital data reported for this period type.
Other Working Capital vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $94.98M USD | +941.2% | +304.5% | 119.1% | |
| LTM Mar 2026 | $43.07M USD | -54.4% | +84.6% | 60.0% | |
| LTM Mar 2026 | $20.91M USD | +15.2% | — | 65.2% | |
| LTM Mar 2026 | $19.64M USD | -71.6% | +51.1% | 43.3% | |
| LTM Mar 2026 | €10.48M EUR | -2.6% | +49.7% | 78.0% | |
| LTM Mar 2026 | $8.34M USD | — | — | 905.3% | |
| FY2025 | $3.93M USD | — | — | 21.1% | |
| LTM Mar 2026 | $2.87M USD | -105.6% | -44.9% | 71.1% | |
| LTM Mar 2026 | $998.82K USD | +76.5% | — | — | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | -2.6% | +51.1% | 68.1% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.